Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation.
Analyst Price Forecast Suggests 68.81% Upside
As of November 21, 2024, the average one-year price target for Sarepta Therapeutics is $192.83/share. The forecasts range from a low of $148.59 to a high of $229.95. The average price target represents an increase of 68.81% from its latest reported closing price of $114.23 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sarepta Therapeutics is 2,022MM, an increase of 23.27%. The projected annual non-GAAP EPS is 2.68.
What is the Fund Sentiment?
There are 1,013 funds or institutions reporting positions in Sarepta Therapeutics. This is an increase of 65 owner(s) or 6.86% in the last quarter. Average portfolio weight of all funds dedicated to SRPT is 0.30%, an increase of 8.23%. Total shares owned by institutions increased in the last three months by 5.11% to 108,868K shares. 
The put/call ratio of SRPT is 0.70, indicating a bullish outlook.
What are Other Shareholders Doing?
BlackRock holds 11,023K shares representing 11.54% ownership of the company. In its prior filing, the firm reported owning 10,324K shares , representing an increase of 6.34%. The firm decreased its portfolio allocation in SRPT by 21.72% over the last quarter.
Capital International Investors holds 6,259K shares representing 6.55% ownership of the company. In its prior filing, the firm reported owning 4,321K shares , representing an increase of 30.97%. The firm increased its portfolio allocation in SRPT by 6.76% over the last quarter.
Janus Henderson Group holds 4,359K shares representing 4.56% ownership of the company. In its prior filing, the firm reported owning 3,815K shares , representing an increase of 12.46%. The firm decreased its portfolio allocation in SRPT by 70.03% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 2,940K shares representing 3.08% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,851K shares representing 2.98% ownership of the company. In its prior filing, the firm reported owning 2,796K shares , representing an increase of 1.93%. The firm increased its portfolio allocation in SRPT by 21.01% over the last quarter.
Sarepta Therapeutics Background Information
(This description is provided by the company.)
Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
